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Background: β-adrenergic receptors play an important role in mitigating the pressor
effects of sympathetic nervous system activity in young women. Based on recent data
showing oral contraceptive use in women abolishes the relationship between muscle
sympathetic nervous system activity and blood pressure, we hypothesized forearm blood
flow responses to a β-adrenergic receptor agonist would be greater in young women
currently using oral contraceptives (OC+, n = 13) when compared to those not using
oral contraceptives (OC–, n = 10).
Methods: Women (18–35 years) were studied during the early follicular phase
of the menstrual cycle (days 1–5) or placebo phase of oral contraceptive use.
Forearm blood flow (FBF, Doppler ultrasound) and mean arterial blood pressure (MAP,
brachial arterial catheter) were measured at baseline and during graded brachial
artery infusion of the β-adrenergic receptor agonist, Isoproterenol (ISO), as well
as Acetylcholine (ACH, endothelium-dependent vasodilation) and Nitroprusside (NTP,
endothelium-independent vasodilation). Forearm vascular conductance was calculated
(FVC = FBF/MAP, ml/min/100 mmHg) and the rise in FVC from baseline during infusion
quantified vasodilation (1FVC = FVCinfusion − FVCbaseline).
Results: ISO increased FVC in both groups (p < 0.01) and ISO-mediated ∆FVC was
greater in OC+ compared to OC– (Main effect of group, p = 0.02). Expressing data as
FVC and FBF resulted in similar conclusions. FVC responses to both ACH and NTP were
also greater in OC+ compared to OC–.
Conclusions: These data are the first to demonstrate greater β-adrenergic
receptor-mediated vasodilation in the forearm of women currently using oral
contraceptives (placebo phase) when compared to those not using oral contraceptives
(early follicular phase), and suggest oral contraceptive use influences neurovascular
control.
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INTRODUCTION
Approximately 80% of American women will use oral
contraceptives in their lifetimes (Shufelt and Bairey Merz, 2009;
Boldo andWhite, 2011; Maguire andWesthoff, 2011). Therefore,
understanding how oral contraceptives alter β-adrenergic
mediated vasodilation and influence neurovascular control holds
great clinical relevance. Although oral contraceptive use has
been linked to improved vascular function, including increases
in endothelial dependent vasodilation (Simoncini et al., 2007;
Meendering et al., 2010), there are consistent reports that women
using oral contraceptive pills exhibit higher systemic blood
pressure (Narkiewicz et al., 1995; Cardoso et al., 1997; Boldo and
White, 2011; Brito et al., 2011; Maguire and Westhoff, 2011).
β-adrenergic receptors are known to play an important role
in mitigating the pressor effects of sympathetic nervous system
activity in young women (Hart et al., 2011). For example,
young men exhibit a positive relationship between sympathetic
nervous system activity and total peripheral resistance (Hart
et al., 2011). This relationship, however, is only observed in
young women following β-adrenoceptor blockade (Hart et al.,
2011). With this information in mind, we sought to examine
the effect of current oral contraceptive use on β-adrenergic
receptor mediated vasodilation using an isolated forearm model.
Based on recent data showing oral contraceptive use in women
abolishes the relationship between muscle sympathetic nervous
system activity and blood pressure when assessed during the
early follicular/placebo pill phase (Harvey et al., 2015), we
hypothesized β-adrenergic receptor mediated vasodilation would
be greater in young, healthy women using oral contraceptives
(placebo phase) when compared to those not currently using oral
contraceptives (early follicular phase).
MATERIALS AND METHODS
A retrospective analysis was conducted on data collected from
33 women who participated in two previous studies from
our laboratory between May 2012 and March 2015 (Harrell
et al., 2015; Limberg et al., 2016). All women were healthy,
non-smokers, non-obese, were not taking any cardiovascular
medications and reported being sedentary (<60 min of aerobic
exercise per week, as determined by self-report). Because the
risk of adverse events with oral contraceptive use increases
with age and use is not encouraged in women who are >35
years, we restricted our study participants to premenopausal
women between the ages of 18 and 35 years (Harvey et al.,
2015). From the 33 women initially studied, 2 women >35
years of age were excluded and 8 women taking non-oral
forms of hormonal contraception (e.g., intrauterine device,
transdermal patch, vaginal ring, etc.) were also excluded.
Women were not pregnant (confirmed by negative pregnancy
test on the study day) and were studied during the early
follicular phase (day 1–5) of the menstrual cycle or placebo
phase of oral contraceptive use (i.e., >24 h following the last
“active” pill; type of oral contraceptive was not controlled for;
see Table S1). This was confirmed by the start of menses
1–5 days before study participation. Subjects underwent a
minimum 10-h fast, and refrained from exercise, non-steroidal
anti-inflammatory drugs, alcohol, and caffeine for 24-h prior
to the study visit. Written informed consent was obtained
from all subjects. All procedures were approved by the
Institutional Review Board at the University of Wisconsin—
Madison and conformed to the standards set by the Declaration
of Helsinki.
Forearm blood flow (artery diameter, blood velocity) was
measured using Doppler ultrasound (Vivid 7, General Electric;
Milwaukee, WI, USA) with the subject resting supine using
methods published previously (Limberg et al., 2013; Ranadive
et al., 2014; Kellawan et al., 2015). TheDoppler audio information
from the ultrasound was converted into a digital signal using
Fast Fourier Transform (Herr et al., 2010). Beat-to-beat brachial
artery blood velocity and blood pressure (Arterial catheter;
Transpac IV Monitoring Kit; ICUmedical; San Clemente, CA)
were obtained throughout each trial.
Microvascular function was assessed by local infusion of
drugs via brachial artery catheter, a widely accepted approach
(Dwivedi et al., 2005; Casey and Joyner, 2011; Casey et al.,
2011; Joyner and Casey, 2015). The brachial artery catheter
was placed in the antecubital fossa of the non-dominant arm
(the dominant arm was studied in 1 woman in the oral
contraceptive group due to variations in the branching pattern
of the brachial artery in the non-dominant arm that precluded
study with Doppler ultrasound). All drugs were dosed to lean
forearm mass as determined by DEXA using doses similar
to those published previously. Isoproterenol (Isoproterenol
Hydrochloride Injection, Marathon Pharmaceuticals, LLC) was
infused at four separate doses (1, 3, 6, and 12 ng/100 g lean
tissue/min) to assess β-adrenergic receptormediated vasodilation
(Eisenach et al., 2006, 2014; Harvey et al., 2014). Nitroprusside
(Nitropress, Hospira Inc) was infused at 3 separate doses (0.5,
1.0, and 2.0 µg/100 g lean tissue/min) to assess smooth muscle
responsiveness to exogenous nitric oxide (Harrell et al., 2015).
Due to the retrospective nature of the study, Acetylcholine
(Michol-E, Novartis Pharmaceuticals) was infused at 3 separate
doses (1, 4, and 16 µg/100 g lean tissue/min) to assess
endothelial function in a sub-set of subjects (Control, n = 6;
Oral Contraceptive, n = 8) (Harrell et al., 2015). Each trial
(Isoproterenol, Nitroprusside, Acetylcholine) was separated by a
minimum of 10 min to ensure hemodynamic variables returned
to baseline levels and drug orders were randomized. Trials
consisted of 2 min of resting data followed by a 3-min infusion
of each drug dose (for a total of ∼9–12 min per infusion
trial).
Data were sampled in real time with signal-processing
software (PowerLab, ADinstruments, Colorado Springs, CO),
digitized, and analyzed off-line. Post-processing using PowerLab
Chart5 software yielded mean blood velocity and blood pressure.
Steady-state hemodynamics were measured during the last 30-
s of saline and each drug dose. Diameter measurements were
taken immediately before increasing dosage, were assessed off-
line from B-mode images, and were taken as the median of five
measurements in late diastole. Blood flow was calculated as the
product of mean blood velocity (cm/s) and vessel cross sectional
area (radius in cm2) and was reported inmL/min/100 g leanmass
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[(blood velocity) (cross sectional area) (60 s/min)÷ forearm lean
mass]. To account for potential changes in blood pressure and
assess vasodilation, vascular conductance (mL/min/100 g/100
mmHg) was calculated [Blood flow ÷ Mean arterial blood
pressure].
The primary analysis was to examine the effect of current
oral contraceptive use on Isoproterenol-mediated vasodilation.
The secondary analysis was to examine the effect of current oral
contraceptive use on Nitroprusside- and Acetylcholine-mediated
vasodilation. To account for any group differences in resting
vascular conductance, the main dependent variable was a change
in forearm vascular conductance (FVC) from baseline levels
(1FVC= FVCcondition − FVCrest).
Statistical analysis was completed using SigmaStat 12.0
software (Systat Software Inc., San Jose, CA, USA). Subject
characteristics were compared using a Student’s unpaired t-test,
and hemodynamic variables were analyzed using an analysis of
variance approach to determine the significance of the fixed effect
of group and dose, in addition to group-by-dose interactions.
Student-Neuman-Keuls post hoc comparisons were performed
when significant effects were observed. All data are presented
as Mean ± Standard error of the mean, and significance was
determined a priori at p≤ 0.05. Sample size was determined using
group differences from previously published data [minimum
detectable difference in means of 1.9 mL/min/100 mL/mmHg;
expected standard deviation of residuals of 1.4mL/min/100
mL/mmHg] (Harvey et al., 2014).With these data, we determined
10 subjects would provide 80% power to detect a significant
difference in forearm vascular conductance at the α= 0.05 level.
RESULTS
Data from 23 young, healthy women (Control, n = 10; Oral
contraceptive, n = 13) were included in the current study
(Table 1). Groups were not different in regard to age, height,
weight, body mass index, lean forearm mass, or fasting glucose
levels (p > 0.05). Women currently taking oral contraceptives
exhibited significantly higher body fat and total cholesterol
when compared to control women (Table 1; p = 0.01 and p
< 0.01, respectively). In addition, mean arterial blood pressure
(∼2–4 mmHg) and heart rate (∼5–10 beat/min) were elevated in
women currently taking oral contraceptives when compared with
control women (Tables 2–4). No group differences in brachial
artery diameter were observed under any condition (Tables 2–4).
Isoproterenol infusion (Control, n = 10; Oral contraceptive,
n = 13) resulted in a dose-dependent increase in vascular
conductance (Table 2, Figure 1; Main effect of ISO p < 0.001).
Isoproterenol-mediated vasodilation was greater in women
taking oral contraceptives when compared to control women
(Figure 1; Main effect of group, p = 0.002). Similarly, the rise
(1) in vascular conductance from baseline with Isoproterenol
infusion was greater in women taking oral contraceptives when
compared to controls (Figure 1; Main effect of group, p =
0.012). No group-by-dose interactions were observed. Similar
observations were made when results were assessed as forearm
blood flow.
TABLE 1 | Subject Demographics.
Control Oral Contraceptive p-value
(n = 10) (n = 13)
Age (yrs) 24±1 22± 1 0.22
Height (cm) 165±2 167± 1 0.49
Weight (kg) 57±2 62± 1 0.06
BMI (kg/m2) 21±1 22± 1 0.09
Body fat (%) 29±2 36± 1 0.01
Lean forearm mass (g) 555±24 589± 19 0.27
Glucose (mg/dL) 75±2 70± 3 0.19
Total cholesterol (mg/dL) 142±8 189± 10 <0.01
Data are presented as Mean ± SEM. BMI = body mass index. Body fat determined by
DEXA. Bold values highlight significance.
Acetylcholine was infused in a sub-set of subjects (Control,
n= 6; Oral Contraceptive, n= 8). Acetylcholine infusion resulted
in a dose-dependent increase in vascular conductance (Table 3,
Figure 2; Main effect of ACH p< 0.001). Acetylcholine-mediated
vasodilation was greater in women taking oral contraceptives
when compared to control women (Figure 2; Main effect of
group, p= 0.007). Similarly, the rise (1) in vascular conductance
from baseline with Acetylcholine infusion was greater in women
taking oral contraceptives when compared to controls (Figure 2;
Main effect of group, p = 0.006). No group-by-dose interactions
were observed. Similar observations were made when results
were assessed as forearm blood flow.
Nitroprusside infusion (Control, n = 10; Oral contraceptive,
n = 13) resulted in a dose-dependent increase in vascular
conductance (Table 4, Figure 3; Main effect of NTP p < 0.001).
Nitroprusside-mediated vasodilation was greater in women
taking oral contraceptives when compared to control women
(Figure 3; Main effect of group, p = 0.015). Similarly, the rise
(1) in vascular conductance from baseline with Nitroprusside
infusion was greater in women taking oral contraceptives when
compared to controls (Figure 3; Main effect of group, p =
0.032). No group-by-dose interactions were observed. Similar
observations were made when results were assessed as forearm
blood flow.
DISCUSSION
This is the first study to directly test the hypothesis that oral
contraceptive use increases β-adrenergic vasodilation. Novel
findings from the present study show that Isoproterenol-
mediated vasodilation in the forearm is higher in young
women currently using oral contraceptives when compared to
women with natural menstrual cycles studied during the placebo
pill/early follicular phase (Table 2, Figure 1).
There are several mechanisms by which oral contraceptive
use may increase β-adrenergic receptor mediated vasodilation.
First, although doses of estradiol used in oral contraceptive pills
are considered very low, they are physiologically higher than
naturally circulating sex hormones. Estrogen can increase nitric
oxide availability (Kleinert et al., 1998; Cicinelli et al., 1999)
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TABLE 2 | Effect of Isoproterenol in women using oral contraceptives.
Control Oral Main Main
(n = 10) Contraceptive effect of effect of
(n = 13) Isoproterenol Group
DIAMETER (cm)
Baseline 0.33±0.01 0.33± 0.01 0.565 0.885
1 ng/100 g/min 0.34±0.01 0.34± 0.01
3 ng/100 g/min 0.34±0.01 0.34± 0.01
6 ng/100 g/min 0.34±0.01 0.34± 0.01
12 ng/100 g/min 0.34±0.01 0.35± 0.01
HEART RATE (beats/min)
Baseline 57±3 66± 2 0.929 <0.001
1 ng/100 g/min 60±2 65± 2
3 ng/100 g/min 59±3 65± 2
6 ng/100 g/min 59±3 66± 2
12 ng/100 g/min 59±3 68± 2
MEAN ARTERIAL BLOOD PRESSURE (mmHg)
Baseline 83±2 87± 2 0.0963 0.002
1 ng/100 g/min 83±2 86± 2
3 ng/100 g/min 81±2 86± 2
6 ng/100 g/min 82±2 87± 2
12 ng/100 g/min 82±3 87± 3
FOREARM BLOOD FLOW (mL/min/100 g)
Baseline 4.9±0.9 6.1± 0.6 <0.001 <0.001
1 ng/100 g/min 7.1±0.8 9.0± 0.8
3 ng/100 g/min 9.3±0.9A 13.0± 1.1A
6 ng/100 g/min 13.4±1.8ABC 17.7± 1.8ABC
12 ng/100 g/min 16.0±1.7ABC 21.6± 1.9ABC
FOREARM VASCULAR CONDUCTANCE (mL/min/100 g/100 mmHg)
Baseline 5.8±1.0 7.1± 0.7 <0.001 0.002
1 ng/100 g/min 8.4±0.8 10.6± 1.1
3 ng/100 g/min 11.4±0.9A 15.5± 1.6A
6 ng/100 g/min 16.4±2.2ABC 20.9± 2.6ABC
12 ng/100 g/min 19.3±1.7ABC 25.5± 2.7ABC
Data are presented as Mean ± SEM. Ap < 0.05 vs. Baseline; Bp < 0.05 vs. 1 ng/100
g/min; Cp < 0.05 vs. 3 ng/100 g/min. From the initial model which included Group-by-
Isoproterenol interaction effect, no significant interaction was detected (p > 0.05). Bold
values highlight significance.
and, although controversy exists (Limberg et al., 2016), it is
thought that β-adrenergic receptors cause vasodilation partially
through a nitric oxide mechanism (Cardillo et al., 1997; Ferro
et al., 1999; Kneale et al., 2000; Jordan et al., 2001). Second,
oral contraceptives can suppress androgen levels (Wiegratz
et al., 1995; Coenen et al., 1996) and androgen suppression
has been shown to increase endothelium-dependent vasodilation
(Herman et al., 1997). Third, estrogen may also have a direct
effect on β-adrenergic receptors through an endothelium-
independent mechanism (Ferrer et al., 1996). With these ideas
in mind, we explored potential differences in smooth muscle
responsiveness to exogenous nitric oxide (Nitroprusside) and/or
endothelium-dependent vasodilation (Acetylcholine) between
women currently using oral contraceptives and women with
natural menstrual cycles.
TABLE 3 | Effect of Acetylcholine in women using oral contraceptives.
Control Oral Main Main
(n = 6) Contraceptive effect of effect of
(n = 8) Acetylcholine Group
Diameter (cm)
Baseline 0.35±0.02 0.34± 0.01 0.090 0.582
1 µg/100 g/min 0.34±0.02 0.35± 0.01
4 µg/100 g/min 0.36±0.02 0.37± 0.01
16 µg/100 g/min 0.37±0.02 0.38± 0.01
Heart Rate (beats/min)
Baseline 54±3 65± 3 0.983 <0.001
1 µg/100 g/min 55±3 66± 3
4 µg/100 g/min 54±3 64± 2
16 µg/100 g/min 56±4 64± 2
Mean Arterial Blood Pressure (mmHg)
Baseline 83±4 85± 3 0.843 0.905
1 µg/100 g/min 83±3 84± 3
4 µg/100 g/min 81±4 81± 3
16 µg/100 g/min 83±5 81± 3
Forearm Blood Flow (mL/min/100 g)
Baseline 7.0±1.0 6.8± 0.8 <0.001 0.004
1 µg/100 g/min 8.7±2.6 13.2± 4.7
4 µg/100 g/min 21.9±5.7AB 35.5± 6.3AB
16 µg/100 g/min 33.3±5.1ABC 62.0± 8.8ABC
Forearm Vascular Conductance (mL/min/100 g/100 mmHg)
Baseline 8.2±0.9 8.1± 1.1 <0.001 0.007
1 µg/100 g/min 10.5±3.4 16.0± 5.9
4 µg/100 g/min 27.9±7.8AB 43.2± 7.6AB
16 µg/100 g/min 41.9±7.4ABC 76.2± 10.8ABC
Data are presented as Mean ± SEM. Ap < 0.05 vs. Baseline; Bp < 0.05 vs. 1 µg/100
g/min; Cp < 0.05 vs. 4 µg/100 g/min. From the initial model which included Group-by-
Acetylcholine interaction effect, no significant interaction was detected (p > 0.05). Bold
values highlight significance.
We observed higher Acetylcholine-mediated vasodilation in
the women using oral contraceptive pills when compared to
women with natural menstrual cycles (Figure 2). In contrast,
Virdis and colleagues reported that 6-months of hormonal
contraceptive use did not affect microcirculatory responses
to Acetylcholine (Virdis et al., 2003). Additionally, John and
colleagues found similar Acetylcholine-mediated vasodilation
between women using oral contraception versus those who were
not currently using oral contraceptive pills (John et al., 2000).
However, both studies focused on women during the follicular
phase of the menstrual cycle (∼day 12), characterized by high
serum estradiol levels (John et al., 2000; Virdis et al., 2003). With
our new findings, it appears that improvements in endothelial
function with oral contraceptive use may be similar in magnitude
to increased function observed during the follicular phase of the
menstrual cycle in normally cycling women.
Vasodilatory responses to exogenous nitric oxide
administration (Nitroprusside) have been shown to be similar
between women using oral contraceptive pills and those with
natural menstrual cycles (John et al., 2000; Virdis et al., 2003).
In contrast, we found that women using oral contraceptives
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TABLE 4 | Effect of Nitroprusside in women using oral contraceptives.
Control Oral Main Main
(n = 10) Contraceptive effect of effect of
(n = 13) Nitroprusside Group
Diameter (cm)
Baseline 0.34± 0.01 0.33± 0.01 <0.001 0.072
0.5 µg/100 g/min 0.35± 0.01A 0.35± 0.01A
1.0 µg/100 g/min 0.37± 0.01A 0.36± 0.01A
2.0 µg/100 g/min 0.39± 0.01ABC 0.38± 0.01ABC
Heart Rate (beats/min)
Baseline 59± 3 65± 3 0.329 <0.001
0.5 µg/100 g/min 57± 2 68± 4
1.0 µg/100 g/min 60± 2 71± 3
2.0 µg/100 g/min 62± 3 72± 3
Mean Arterial Blood Pressure (mmHg)
Baseline 86± 3 90± 2 0.009 0.039
0.5 µg/100 g/min 79± 3A 85± 3A
1.0 µg/100 g/min 79± 3A 82± 2A
2.0 µg/100 g/min 78± 2A 80± 3A
Forearm Blood Flow (mL/min/100 g)
Baseline 5.8± 0.9 6.9± 0.7 <0.001 0.004
0.5 µg/100 g/min 20.3± 3.5A 24.0± 2.7A
1.0 µg/100 g/min 22.8± 3.9A 32.2± 3.5A
2.0 µg/100 g/min 28.6± 5.0ABC 40.7± 3.1ABC
Forearm Vascular Conductance (mL/min/100 g/100 mmHg)
Baseline 6.7± 0.9 7.7± 0.8 <0.001 0.015
0.5 µg/100 g/min 25.6± 4.3A 28.6± 3.8A
1.0 µg/100 g/min 28.9± 4.9A 39.7± 4.9A
2.0 µg/100 g/min 36.7± 6.2ABC 53.0± 5.7ABC
Data are presented as Mean ± SEM. Ap < 0.05 vs. Baseline; Bp < 0.05 vs. 0.5 µg/100
g/min; Cp < 0.05 vs. 1.0 µg/100 g/min. From the initial model which included Group-by-
Nitroprusside interaction effect, no significant interaction was detected (p > 0.05). Bold
values highlight significance.
demonstrated greater Nitroprusside responses (Figure 3). As
noted above, differences in study design (studying women on
days 1–5 vs. day 12 of the menstrual cycle) may have contributed
to discrepancies between findings. On the other hand, L-NMMA
(a nitric oxide synthase inhibitor) reduced basal forearm
blood flow more in women using oral contraception when
compared to those without (John et al., 2000). Taken together,
it is reasonable to propose: (1) the vascular smooth muscle is
more responsive to exogenous nitric oxide in women currently
using oral contraceptives (Figure 3), (2) oral contraceptive
use increases nitric oxide production and/or release (John
et al., 2000), and/or (3) any increase in responsiveness to
nitric oxide may be due to changes in female sex hormone
levels (John et al., 2000). Future studies using nitric oxide
synthase inhibition will be necessary to adequately address such
possibilities.
CLINICAL IMPLICATIONS
Approximately 80% of women in the United States will use
oral contraceptive pills during their lifetime (Shufelt and Bairey
FIGURE 1 | Effect of Isoproterenol on forearm vascular conductance in
women using oral contraceptives. (Control, n = 10; Oral contraceptive, n
= 13) Isoproterenol infusion resulted in a dose-dependent increase in vascular
conductance in both groups (p < 0.001). The rise in vascular conductance
from baseline with Isoproterenol infusion was greater in women taking oral
contraceptives when compared to controls (p = 0.012). Data are presented as
Mean ± SEM. *p < 0.05 vs. Control; Bp < 0.05 vs. 1 ng/100 g/min; Cp
< 0.05 vs. 3 ng/100 g/min.
FIGURE 2 | Effect of Acetylcholine on forearm vascular conductance in
women using oral contraceptives. (Control, n = 6; Oral contraceptive, n =
8) Acetylcholine infusion resulted in a dose-dependent increase in vascular
conductance (p < 0.001). The rise in vascular conductance from baseline with
Acetylcholine infusion was greater in women taking oral contraceptives when
compared to controls (p = 0.006). Data are presented as Mean ± SEM. *p
< 0.05 vs. Control; Bp < 0.05 vs. 1 µg/100 g/min; Cp < 0.05 vs. 4
µg/100 g/min.
Merz, 2009; Boldo and White, 2011; Maguire and Westhoff,
2011). Present novel findings indicate oral contraceptive use
produces a broad, positive impact on peripheral skeletal muscle
microvascular function, including greater β-adrenergic receptor
mediated vasodilation, as well as endothelium-dependent and
-independent vasodilation that is observed even during the
placebo pill phase. Consistent with greater vasodilation, women
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FIGURE 3 | Effect of Nitroprusside on forearm vascular conductance in
women using oral contraceptives. (Control, n = 10; Oral contraceptive,
n = 13) Nitroprusside infusion resulted in a dose-dependent increase in
vascular conductance. The rise in vascular conductance from baseline with
Nitroprusside infusion was greater in women taking oral contraceptives when
compared to controls (p = 0.032). Data are presented as Mean±SEM. *p
< 0.05 vs. Control; Bp < 0.05 vs. 0.05 µg/100 g/min; Cp < 0.05 vs/ 1.0
µg/100 g/min.
using oral contraceptives appear to exhibit less sympathetic
support of blood pressure (Harvey et al., 2015). Many have
speculated this effect to be due to greater β-adrenergic receptor
mediated vasodilation (Hart et al., 2011; Joyner et al., 2016)
and our data directly support this hypothesis. With this
in mind, it may be surprising that the women currently
using oral contraceptives exhibited mildly elevated blood
pressures (∼2–4 mmHg) when compared with control women
(Tables 2–4). Oral contraceptive use has been associated with
increased blood pressure (Narkiewicz et al., 1995; Cardoso et al.,
1997; Boldo and White, 2011; Brito et al., 2011; Maguire and
Westhoff, 2011) independent of changes in muscle sympathetic
nervous system activity (Harvey et al., 2015). Although exact
mechanisms are unknown, this may be the result of increased
plasma volume (Stachenfeld and Taylor, 2005; Cherney et al.,
2007) and/or increased activity of the renin-angiotensin-
aldosterone system (Gordon et al., 1992; Oelkers, 1996; Kang
et al., 2001). Therefore, despite the positive impact of oral
contraceptive use on peripheral vascular function—as suggested
by the present findings—combined effects of oral contraceptives
on other physiological control mechanisms likely attenuate this
“protective effect” when systemic blood pressure is examined.
However, any effect is likely cyclical, given blood pressure
is often lower during the active phase of oral contraceptive
use when compared to the placebo phase (Meendering et al.,
2010).
EXPERIMENTAL CONSIDERATIONS
This is the first study to examine β-adrenergic receptor
mediated vasodilation in women using oral contraceptives and
potential contributing mechanisms. Despite this, there are some
important experimental considerations. First, this study is a
post-hoc analysis and therefore women were taking different
formulations of oral contraceptive pills. However, the majority
(70%) of participants were known to be using third- and fourth-
generation formulations (Supplemental Table S1), which have
been shown to have beneficial, rather than detrimental, effects
on endothelial function (Simoncini et al., 2007; Meendering
et al., 2010) and this is reflected in observed increases in
endothelium-dependent vasodilation. Second, the duration of
oral contraceptive use is unknown; however, duration of
contraceptive use has been shown previously to have little-to-
no effect on vascular function (Friedman et al., 2011). Third,
women taking oral contraceptives had significantly higher body
fat percentage, blood pressure, and total cholesterol (Tables 1–
2). Consistent with this, changes in lipid profile have been
shown previously with oral contraceptive use (Sitruk-Ware, 2006;
Shufelt and Bairey Merz, 2009). However, these factors should
contribute to lower endothelium-dependent vasodilation, rather
than higher (Virdis et al., 2003) and therefore would likely lead us
to underestimate group differences. Lastly, we did not measure
sex hormone levels. However, based on previous literature,
including data from our laboratory (Peltonen et al., 2015), we
are confident endogenous female sex hormones were low in
both groups when studied during the early follicular/placebo
phases (Aden et al., 1998). Despite relatively low hormone
levels in both groups, significant differences in β-adrenergic
mediated vasodilation were observed. These data may support
the possibility of a carry-over effect from the prior active pill
phase, although future studies will be necessary to examine this
possibility.
CONCLUSION
This is the first study to directly test the hypothesis that
oral contraceptive use increases β-adrenergic receptor mediated
vasodilation in the forearm skeletal muscle microcirculation
of young, premenopausal women. Present novel findings show
greater forearm β-adrenergic receptor mediated vasodilation, as
well as endothelium-dependent and -independent vasodilation,
in women currently using oral contraceptives when studied
during the placebo phase. Taken together, these data provide
important new insight into the effect of oral contraceptive use
on vascular function, which may have important implications for
neurovascular control in both health and disease.
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